Skip to content

MiMedx Group MDXG Payments For Application Costs, Patent

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp
FCF margin17.8%-0.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept mdxg:PaymentsForApplicationCostsPatent.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's payments for application costs, patent.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's payments for application costs, patent?
MiMedx Group (MDXG) reported payments for application costs, patent of $72K in Q1 2026.
How has MiMedx Group's payments for application costs, patent changed year-over-year?
MiMedx Group's payments for application costs, patent increased by 148.3% year-over-year, from $29K to $72K.
What is the long-term trend for MiMedx Group's payments for application costs, patent?
Over 2 years (2021 to 2023), MiMedx Group's payments for application costs, patent has grown at a -18.4% compound annual growth rate (CAGR), from $252K to $168K.